Breakthrough medical technology for the early detection of heart di...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

It is quite remarkable that MyoVista demonstrated a high diagnostic precision in detecting a state of cardiac muscle dysfunction only previously detectable using cardiac ultrasound techniques.”
Partho Sengupta, MD, Professor, Chief of Cardiology and Chair of Cardiac Innovation, WVU Heart & Vascular Institute and Principal Investigator.

The amount of information gleaned from an ECG in this way far surpasses any visual interpretation and expands the diagnostic potential of the 12-lead ECG.”
JACC Editorial Comment by Jeroen Bax MD,
PhD et al.  Dr. Bax is currently the President of the European Society of Cardiology. 

It is remarkable that … diastolic function could be such a powerful predictor of all cause mortality.”  “Ischemia, hypertension, diabetes, valvular disease and reduced systolic dysfunction are all associated with diastolic dysfunction”
Department of Health in Human Services Public Access: Diastolic Dysfunction and Prognosis 2015.



MyoVista wavECG Technology provides breakthrough detection of structural and coronary heart disease at an early stage as well as providing all the conventional ECG information

»  A single 20 second test.
»  Following today’s 12-lead ECG
»  At comparable cost.
»  MyoVista Informatics                        measuring cardiac energy              rather than rhythm. 
»  Significantly improves risk
    stratification for ischemic
 heart disease.
»  Plus all the conventional                resting 12-lead ECG                          information.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.